Category: Featured Story

Memorial Sloan-Kettering Cancer Center (MSKCC) is breaking the mold with a new type of clinical trial, known as a “basket study.” Whereas traditional trials target a particular cancer, MSKCC is leading the way by offering clinical trials for anti-cancer drugs that focus on a specific biomarker or genetic mutation, regardless of the type of cancer. …

Chemotherapy is considered the most effective single modality for the treatment of mesothelioma, an asbestos-caused cancer. However, the cancer has proven to outlive the effects of the drugs, and the average prognosis for mesothelioma patients is typically less than one year. Now, oncologists are hailing the results of an immunotherapy clinical trial for melanoma as …

Stopping tumor growth and preventing metastasis in mesothelioma, which is highly aggressive and resistant to standard cancer treatments, is critical for increasing survival in patients. Now, researchers report that by intercepting a signaling pathway found in mesothelioma they can slow the growth of the insidious cancer. Researchers from Korea found that by targeting and blocking …